Holen Sie sich die Stockscreener-App
5.58
5.84%
0.355
Handel nachbörslich:
5.55
-0.03
-0.54%
Schlusskurs vom Vortag:
$5.225
Offen:
$5.26
24-Stunden-Volumen:
20,816
Relative Volume:
0.28
Marktkapitalisierung:
$17.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.52M
KGV:
-0.5737
EPS:
-9.7265
Netto-Cashflow:
$-31.51M
1W Leistung:
+8.86%
1M Leistung:
-5.31%
6M Leistung:
-38.49%
1J Leistung:
+1,395%
1-Tages-Spanne:
$4.97
$5.58
1-Wochen-Bereich:
$4.97
$5.52
52-Wochen-Spanne:
$0.3195
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
5.58 | 16.76M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-04-21 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-03-31 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-10 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio Shareholders Approve Directors and Executive Pay - TipRanks
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentMarket Buzz Alerts - Newser
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Operational ProgressCrowd Sentiment Entry - Newser
PASG Technical Analysis & Stock Price Forecast - Intellectia AI
Passage Bio Inc. (PASG) Holds Steady Near Support as Biotechnology Sector Faces HeadwindsBeta Neutral Pair - Newser
Director Sondhi Dolan receives 10,539 Passage BIO (PASG) stock options - Stock Titan
Passage BIO (NASDAQ: PASG) director Derrell Porter receives grant of 10,539 stock options - Stock Titan
Passage BIO, Inc. (PASG) director gets 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director Sandip Kapadia awarded 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director receives 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) awards 10,539 options to director at $5.08 - Stock Titan
Passage Bio Inc stock (US70267E1055): gene therapy developer back in focus after recent moves - AD HOC NEWS
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Passage Bio Inc stock (US70267E1055): gene therapy hopes meet analyst caution - AD HOC NEWS
Passage Bio stock (US70267E1055): Cuts 75% of workforce after FDA feedback - AD HOC NEWS
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
TradingKey - TradingKey
Krabbe Disease Treatment Market to Reach USD 786.45 Million - openPR.com
TD Cowen Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
MSN Money - MSN
GM1 Gangliosidosis Treatment Market to Reach USD 626.86 Million - openPR.com
Passage BIO, Inc. 1Q 2026: Net loss $(7.6)M, EPS $(2.36) — 10-Q Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Passage Bio (NASDAQ: PASG) faces cash shortfall, cuts workforce 75% - Stock Titan
CCORF Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Why Passage Bio (PASG) business model holds up in any market (Smart Money Active) 2026-05-11Social Flow Trades - newser.com
A Quick Look at Today's Ratings for Passage Bio(PASG.US), With a Forecast Between $21 to $32 - Moomoo
Number of shareholders of Passage Bio, Inc. – BOATS:PASG - TradingView
A Quick Look at Today's Ratings for Passage Bio(PASG.US), With a Forecast Between $8 to $23 - Moomoo
Passage Bio Inc expected to post a loss of $2.79 a shareEarnings Preview - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Layoff Tracker: Passage axes 75% of staff, explores strategic alternatives - BioSpace
Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
PASG (Passage Bio) reports wider-than-expected Q4 2025 loss, shares dip 1.02% amid negative investor sentiment.Retail Trader Ideas - Newser
Canaccord Genuity Remains a Buy on Passage Bio (PASG) - The Globe and Mail
PASG Maintains Rating by Oppenheimer -- Price Target Lowered to $15 - GuruFocus
PASG Downgraded by Chardan Capital -- Price Target Lowered to $7 - GuruFocus
Passage Bio (PASG) Downgraded by Wedbush Analyst - GuruFocus
PASG Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - marketscreener.com
PASG Downgraded by Wedbush -- Price Target Lowered to $8.00 - GuruFocus
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - marketscreener.com
Passage Bio downgraded to Neutral from Buy at Chardan - TipRanks
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday - Benzinga
Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news - Investing.com South Africa
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Passage Bio Inc-Aktie (PASG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Borthwick Kathleen | CFO |
Jan 08 '26 |
Sale |
18.44 |
2,062 |
38,022 |
5,402 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):